Moshik Cohen-Kutner
CEO
Omnix Medical
Omnix Medical develops selective, degradation-resistant antimicrobial peptides to combat infections caused by drug-resistant bacteria. Their technology addresses the urgent need for effective treatments against resistant pathogenic strains, significantly improving patient outcomes in the face of rising antibiotic resistance.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$11.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Niv Bachnoff
CSO
Product
Problem
Drug-resistant bacteria pose a significant threat, especially in hospital-acquired infections, due to the limited effectiveness of existing antibiotics. The rise of multi-drug resistant strains necessitates new therapeutic approaches to combat these infections.
Solution
Omnix Medical is developing a novel class of antimicrobial peptides (AMPs) to address infections caused by drug-resistant Gram-negative bacteria. Their technology overcomes the limitations of traditional antibiotics by utilizing a unique mechanism of action that physically disrupts bacterial cell membranes, leading to rapid bacterial destruction. The AMPs are biochemically engineered for enhanced selectivity and stability, reducing the potential for resistance development. OMN6, the lead compound, has demonstrated promising safety, tolerability, and pharmacokinetic profiles in clinical trials, supporting its further development as a therapeutic option for severe infections.
Target Audience
The primary target audience includes patients with life-threatening hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by Gram-negative bacteria, particularly Acinetobacter baumannii, as well as healthcare providers seeking new treatment options for these infections.
Features
- Novel antimicrobial peptides based on insect host defense mechanisms
- Unique mechanism of action that disrupts bacterial cell membranes
- Selective for Gram-negative bacteria, minimizing off-target effects
- Biochemically engineered for enhanced stability and resistance to degradation
- Demonstrated efficacy in pre-clinical infection models
- OMN6 has shown a favorable safety, tolerability, and pharmacokinetic profile in Phase 1 clinical trials
- Fast-track designation from the U.S. FDA for OMN6